Delcath Systems Q2 2026 Earnings Report

Delcath Systems EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.09
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Delcath Systems Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $26.26 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Delcath Systems Announcement Details

• Quarter: Q2 2026
• Date: 8/6/2026
• Time: Before Market Opens
• Conference Call Date: Thursday, August 6, 2026
• Conference Call Time: 8:30AM ET

Delcath Systems (NASDAQ:DCTH) is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma. Delcath’s approach aims to improve tumor response rates and extend progression-free survival for patients with limited treatment options.

The Hepatic CHEMOSAT® Delivery System comprises specialized catheters, an extracorporeal filtration system and an isolation balloon that together isolate the liver’s vasculature, deliver high-dose chemotherapy and filter the returned blood before it reenters the patient’s systemic circulation. Delcath has achieved CE Mark approval in Europe for the treatment of unresectable liver tumors and is advancing its clinical development program in the United States, where it has completed pivotal trials assessing safety and efficacy in patients with ocular melanoma metastases in the liver. The company also continues to explore expanded indications and next-generation applications of its chemosaturation platform.

Headquartered in New York, Delcath Systems operates in key oncology markets across North America and Europe, collaborating with leading cancer centers and interventional radiology departments. The organization is guided by a management team and board of directors with experience in medical device commercialization, oncology drug development and regulatory affairs. Delcath remains committed to advancing targeted regional therapies that address unmet needs in the treatment of liver tumors and improving patient outcomes through innovation and rigorous clinical investigation.